JP7564620B2 - カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 - Google Patents

カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 Download PDF

Info

Publication number
JP7564620B2
JP7564620B2 JP2019548370A JP2019548370A JP7564620B2 JP 7564620 B2 JP7564620 B2 JP 7564620B2 JP 2019548370 A JP2019548370 A JP 2019548370A JP 2019548370 A JP2019548370 A JP 2019548370A JP 7564620 B2 JP7564620 B2 JP 7564620B2
Authority
JP
Japan
Prior art keywords
catecholamine
patient
glucocorticoid receptor
gra
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510011A (ja
JP2020510011A5 (cg-RX-API-DMAC7.html
Inventor
アンドレアス ジー. モライティス,
Original Assignee
コーセプト セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーセプト セラピューティクス, インコーポレイテッド filed Critical コーセプト セラピューティクス, インコーポレイテッド
Publication of JP2020510011A publication Critical patent/JP2020510011A/ja
Publication of JP2020510011A5 publication Critical patent/JP2020510011A5/ja
Priority to JP2022070027A priority Critical patent/JP2022090003A/ja
Priority to JP2024053332A priority patent/JP2024074854A/ja
Application granted granted Critical
Publication of JP7564620B2 publication Critical patent/JP7564620B2/ja
Priority to JP2026061808A priority patent/JP2026099911A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
JP2019548370A 2017-03-09 2018-03-08 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 Active JP7564620B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022070027A JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2024053332A JP2024074854A (ja) 2017-03-09 2024-03-28 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2026061808A JP2026099911A (ja) 2017-03-09 2026-04-03 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
US62/469,296 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022070027A Division JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Publications (3)

Publication Number Publication Date
JP2020510011A JP2020510011A (ja) 2020-04-02
JP2020510011A5 JP2020510011A5 (cg-RX-API-DMAC7.html) 2021-02-18
JP7564620B2 true JP7564620B2 (ja) 2024-10-09

Family

ID=63446773

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019548370A Active JP7564620B2 (ja) 2017-03-09 2018-03-08 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2022070027A Withdrawn JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2024053332A Withdrawn JP2024074854A (ja) 2017-03-09 2024-03-28 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2026061808A Pending JP2026099911A (ja) 2017-03-09 2026-04-03 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022070027A Withdrawn JP2022090003A (ja) 2017-03-09 2022-04-21 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2024053332A Withdrawn JP2024074854A (ja) 2017-03-09 2024-03-28 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
JP2026061808A Pending JP2026099911A (ja) 2017-03-09 2026-04-03 カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用

Country Status (8)

Country Link
US (1) US11045482B2 (cg-RX-API-DMAC7.html)
EP (1) EP3592358A4 (cg-RX-API-DMAC7.html)
JP (4) JP7564620B2 (cg-RX-API-DMAC7.html)
CN (1) CN110475558A (cg-RX-API-DMAC7.html)
AU (1) AU2018230429B2 (cg-RX-API-DMAC7.html)
CA (1) CA3053806A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019010732A (cg-RX-API-DMAC7.html)
WO (1) WO2018165460A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007402A (es) 2018-12-20 2021-07-15 Corcept Therapeutics Inc Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6818739B2 (en) 1999-12-03 2004-11-16 Ndsu Research Foundation Somatostatins
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
JP2004525135A (ja) 2001-03-23 2004-08-19 コーセプト セラピューティクス, インコーポレイテッド 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
RU28362U1 (ru) 2002-12-10 2003-03-20 Закрытое акционерное общество "Дальневосточная технология" Лист заходной футеровки
JP4931794B2 (ja) 2004-03-09 2012-05-16 コーセプト セラピューティクス, インコーポレイテッド 縮合環アザデカリン糖質コルチコイド受容体モジュレーター
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP2145186A4 (en) * 2007-05-15 2010-10-20 Water Technologies Corp DEVICE AND METHOD FOR THE DETECTION OF METANEPHRINES IN PLASMA
EP2532350A1 (en) 2007-10-17 2012-12-12 Laboratoire HRA Pharma Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2943542T3 (es) 2013-11-25 2023-06-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
JP6821582B2 (ja) * 2015-03-02 2021-01-27 コーセプト セラピューティクス, インコーポレイテッド Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
US9943526B2 (en) * 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL OBSTETRICS AND GYNECOLOGY,1996年,Vol.39,No.2,pp.506-510

Also Published As

Publication number Publication date
CN110475558A (zh) 2019-11-19
US20180256604A1 (en) 2018-09-13
CA3053806A1 (en) 2018-09-13
JP2024074854A (ja) 2024-05-31
WO2018165460A1 (en) 2018-09-13
EP3592358A1 (en) 2020-01-15
JP2020510011A (ja) 2020-04-02
EP3592358A4 (en) 2020-12-16
US11045482B2 (en) 2021-06-29
AU2018230429B2 (en) 2023-06-15
JP2022090003A (ja) 2022-06-16
JP2026099911A (ja) 2026-06-18
MX2019010732A (es) 2019-11-01
AU2018230429A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
US11073523B2 (en) Method for differentially diagnosing ACTH-dependent Cushing's syndrome
JP6821582B2 (ja) Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
JP2024074854A (ja) カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
CA2978960C (en) Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
JP2022164775A (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2023052618A (ja) 糖質コルチコイド受容体モジュレータおよびcyp3aインヒビタの併用投与
HK1255714B (en) Method for differentially diagnosing acth-dependent cushing's syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221227

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221228

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230203

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240927

R150 Certificate of patent or registration of utility model

Ref document number: 7564620

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150